Average Co-Inventor Count = 6.89
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Deutsches Krebsforschungszentrum (6 from 155 patents)
2. Ruprecht-karls-universitat Heidelberg (4 from 63 patents)
3. Novartis Ag (2 from 3,923 patents)
4. Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts (2 from 160 patents)
5. Ruprecht-karls-universitaet Heidelberg (2 from 23 patents)
6. Ruprecht-karls-universität (7 patents)
10 patents:
1. 12054458 - F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
2. 11951190 - Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
3. 11931430 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
4. 11045564 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
5. 10815200 - 18F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
6. 10471160 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
7. 10398791 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
8. 10016519 - 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
9. 7145000 - [object Object]
10. 6891033 - Labelling compounds for the simple synthesis of 3'-[18F]fluoro-3'-deoxythymidine and a method for the production thereof